Gene

FGFR3

fibroblast growth factor receptor 3

Explore in graph →CI-GENE-00001926HGNC:3690 ENSG00000068078 NCBI 2261 CIViC Cancer geneApproved

Curated evidence

Clinical evidence (214)

CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.

civicCuratedShowing 201–214 of 214 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
FGFR3 Y373C9
Erdafitinib	Urothelial Carcinoma	Predictive	B	Supports Sensitivity Response	3	submitted	EID13205 In a phase 2 trial of patients with advanced or metastatic urothelial cancer who were positive for FGFR2 fusions or known FGFR3 variants (including Y373C), 40% of patients showed an objective response…

Cohorts

Alteration frequency by cohort (100)

Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.

cbioportalObserved100 cohort rows (showing 50, sorted by frequency) · frequency = affected / profiled, as published by each cohort; cohorts are not pooled. Hover a row badge for its release.

Cohort	Mapped cancer	Alteration	Affected (n)	Profiled (n)	Frequency (%)	Rank in cohort	Source
Bladder Cancer (MSK, Clin Cancer Res 2023) bladder_msk_2023	unmapped	Ssm	443	526

Literature

Linked publications (36)

25 per page, newest first.

pubmedPublishedShowing 1–25 of 36 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma.
· N Engl J Med · 2019 · PMID 31340094 · validated civic_curation pubmed
FGFR3 mutational status and protein expression in patients with bladder cancer in a Jordanian population.
· Cancer Epidemiol · 2010 · PMID 20542753 · validated civic_curation pubmed
Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study.
· J Clin Oncol · 2017 · PMID 27870574 · validated civic_curation pubmed
Somatic FGFR3 Mutations Distinguish a Subgroup of Muscle-Invasive Bladder Cancers with Response to Neoadjuvant Chemotherapy.
· EBioMedicine · 2018 · PMID 29941343

FGFR3 N540K + FGFR3 Y373C1
Erdafitinib + FutibatinibSequential	Urothelial Carcinoma	Predictive	C	Supports Resistance	4	accepted	EID12704 In this study of patients with FGFR-driven urothelial carcinoma treated with selective FGFR inhibitors, longitudinal ctDNA analysis identified emergent FGFR3 kinase domain mutations at disease progres… (full text at CIViC) PMID 37377403 · Facchinetti et al., 2023 · Open in CIViC	civic

FGFR3 N540K + FGFR3 Y373C1

Erdafitinib + FutibatinibSequential

Urothelial Carcinoma

Predictive

Supports Resistance

accepted

EID12704

In this study of patients with FGFR-driven urothelial carcinoma treated with selective FGFR inhibitors, longitudinal ctDNA analysis identified emergent FGFR3 kinase domain mutations at disease progres… (full text at CIViC)

PMID 37377403 · Facchinetti et al., 2023 · Open in CIViC

civic

FGFR3 Y647C3
(functional)	—UNRESOLVED	Functional	D	Supports Gain Of Function	3	accepted	EID13187 Purified FGFR3 protein with the Y647C substitution had higher kinase activity in vitro than wild-type FGFR3 protein, as measured by autophosphorylation. PMID 26992226 · Patani et al., 2016 · Open in CIViC	civic
〃	—UNRESOLVED	Functional	D	Does Not Support Gain Of Function	2	rejected	EID9705 Variant reported within a comprehensive study of FGFRs intracellular variants (highlight in the KD) and insight in FGFR-selective tyrosine kinase inhibitors. Y647C was related to lung cancer, observed… (full text at CIViC) PMID 26992226 · Patani et al., 2016 · Open in CIViC	civic
(oncogenic)	Malignant NeoplasmALIAS	Oncogenic	D	Does Not Support Oncogenicity	2	submitted	EID13202 In a saturation mutagenesis study, all possible point mutations in the FGFR 1-4 kinase domain (amino acids 472-807 for FGFR3) were tested. Lentiviral plasmids were infected at MOI < 0.3 into the growt… (full text at CIViC) PMID 41361008 · Tangermann et al., 2025 · Open in CIViC	civic

FGFR3 Y647C3

(functional)

—UNRESOLVED

Functional

Supports Gain Of Function

accepted

EID13187

Purified FGFR3 protein with the Y647C substitution had higher kinase activity in vitro than wild-type FGFR3 protein, as measured by autophosphorylation.

PMID 26992226 · Patani et al., 2016 · Open in CIViC

civic

〃

—UNRESOLVED

Functional

Does Not Support Gain Of Function

rejected

EID9705

Variant reported within a comprehensive study of FGFRs intracellular variants (highlight in the KD) and insight in FGFR-selective tyrosine kinase inhibitors. Y647C was related to lung cancer, observed… (full text at CIViC)

PMID 26992226 · Patani et al., 2016 · Open in CIViC

civic

(oncogenic)

Malignant NeoplasmALIAS

Oncogenic

Does Not Support Oncogenicity

submitted

EID13202

In a saturation mutagenesis study, all possible point mutations in the FGFR 1-4 kinase domain (amino acids 472-807 for FGFR3) were tested. Lentiviral plasmids were infected at MOI < 0.3 into the growt… (full text at CIViC)

PMID 41361008 · Tangermann et al., 2025 · Open in CIViC

civic

FGFR3 N540K + FGFR3 S249C + PIK3CA E545KPIK3CA FGFR31
Erdafitinib	Urothelial Carcinoma	Predictive	C	Supports Resistance	4	accepted	EID12703 In this study of 21 patients with FGFR-driven urothelial carcinoma treated with selective FGFR inhibitors (including erdafitinib), post-progression molecular analyses (tissue and/or ctDNA sequencing) … (full text at CIViC) PMID 37377403 · Facchinetti et al., 2023 · Open in CIViC	civic

FGFR3 N540K + FGFR3 S249C + PIK3CA E545KPIK3CA FGFR31

Erdafitinib

Urothelial Carcinoma

Predictive

Supports Resistance

accepted

EID12703

In this study of 21 patients with FGFR-driven urothelial carcinoma treated with selective FGFR inhibitors (including erdafitinib), post-progression molecular analyses (tissue and/or ctDNA sequencing) … (full text at CIViC)

PMID 37377403 · Facchinetti et al., 2023 · Open in CIViC

civic